IL315970A - Novel anti-fgfr2 antibodies - Google Patents

Novel anti-fgfr2 antibodies

Info

Publication number
IL315970A
IL315970A IL315970A IL31597024A IL315970A IL 315970 A IL315970 A IL 315970A IL 315970 A IL315970 A IL 315970A IL 31597024 A IL31597024 A IL 31597024A IL 315970 A IL315970 A IL 315970A
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
IL315970A
Other languages
English (en)
Hebrew (he)
Inventor
Tiantian Zhou
Qinglin Du
Shuhua Han
Fei Peng
Xueyan Yang
Original Assignee
Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Tiantian Zhou
Qinglin Du
Shuhua Han
Fei Peng
Xueyan Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd, Tiantian Zhou, Qinglin Du, Shuhua Han, Fei Peng, Xueyan Yang filed Critical Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Publication of IL315970A publication Critical patent/IL315970A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL315970A 2022-03-28 2023-03-28 Novel anti-fgfr2 antibodies IL315970A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022083269 2022-03-28
PCT/CN2023/084213 WO2023185778A1 (en) 2022-03-28 2023-03-28 Novel anti-fgfr2 antibodies

Publications (1)

Publication Number Publication Date
IL315970A true IL315970A (en) 2024-11-01

Family

ID=88199423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315970A IL315970A (en) 2022-03-28 2023-03-28 Novel anti-fgfr2 antibodies

Country Status (9)

Country Link
EP (1) EP4499701A4 (enExample)
JP (1) JP2025513745A (enExample)
KR (1) KR20250042203A (enExample)
CN (1) CN119110806A (enExample)
AU (1) AU2023243773A1 (enExample)
CA (1) CA3246949A1 (enExample)
IL (1) IL315970A (enExample)
MX (1) MX2024011805A (enExample)
WO (1) WO2023185778A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600596A (zh) * 2024-03-04 2026-01-01 大陸商杭州中美華東製藥有限公司 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途
WO2026092428A1 (zh) * 2024-10-28 2026-05-07 湖北生物医药产业技术研究院有限公司 无岩藻糖基化抗FGFR2b单抗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
MX374785B (es) * 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN105792844B (zh) * 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
WO2016171107A1 (ja) * 2015-04-20 2016-10-27 第一三共株式会社 Ｆｇｆｒ２の検出
PE20211213A1 (es) * 2018-10-05 2021-07-05 Five Prime Therapeutics Inc Formulaciones de anticuerpos anti-fgfr2
AR120884A1 (es) * 2019-12-24 2022-03-23 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
JP7685999B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
CN114846029A (zh) * 2019-12-24 2022-08-02 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体

Also Published As

Publication number Publication date
EP4499701A1 (en) 2025-02-05
EP4499701A4 (en) 2026-02-25
CN119110806A (zh) 2024-12-10
JP2025513745A (ja) 2025-04-30
AU2023243773A1 (en) 2024-10-24
MX2024011805A (es) 2024-11-08
KR20250042203A (ko) 2025-03-26
WO2023185778A1 (en) 2023-10-05
CA3246949A1 (en) 2023-10-05
WO2023185778A9 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
US20230399408A1 (en) Multispecific antibodies and uses thereof
JP2020520370A (ja) 抗ＳＩＲＰα抗体
IL295509A (en) Steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses
US12180281B2 (en) Anti-PD-1 antibodies and methods of treating cancer
IL239604A (en) Anti-vegf monoclonal antibodies, binding segments and their uses
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
WO2023185778A1 (en) Novel anti-fgfr2 antibodies
IL309201A (en) Compounds with anticancer activity
JP2023138538A (ja) 抗ｔｎｆｒｓｆ９抗体及びその使用
KR20250028357A (ko) 항-egfr/met 항체 및 이의 용도
JP2020507339A (ja) 抗ｇ−ｃｓｆ抗体及びその使用
IL295979A (en) Anti-cd36 antibodies and their use to treat cancer
TW202221029A (zh) 抗cd93之構築體及其用途
WO2024199362A1 (en) Novel anti-FGFR2 antibodies
KR20200088810A (ko) 항―ｏｘ４０ 항체 및 그의 용도
US20230226206A1 (en) Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination
JP2026500752A (ja) 抗ｂ７ｈ３抗体及びその使用方法
IL322127A (en) Anti-cmet antibodies and methods of use
IL317192A (en) Anti-CDH6 antibody-drug conjugate dosing regimen
JP2024515266A (ja) 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体
JP2025010203A (ja) Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
TW202428608A (zh) 抗b7h3抗體以及其使用方法
CN119095874A (zh) 抗程序性死亡配体1(pd-l1)抗体分子、编码多核苷酸及使用方法
WO2026092306A1 (en) Anti-vegf-a antibodies and uses thereof